220 related articles for article (PubMed ID: 28851888)
1. The Prognostic 97 Chemoresponse Gene Signature in Ovarian Cancer.
Matondo A; Jo YH; Shahid M; Choi TG; Nguyen MN; Nguyen NNY; Akter S; Kang I; Ha J; Maeng CH; Kim SY; Lee JS; Kim J; Kim SS
Sci Rep; 2017 Aug; 7(1):9689. PubMed ID: 28851888
[TBL] [Abstract][Full Text] [Related]
2. Development and validation of an immune gene-set based Prognostic signature in ovarian cancer.
Shen S; Wang G; Zhang R; Zhao Y; Yu H; Wei Y; Chen F
EBioMedicine; 2019 Feb; 40():318-326. PubMed ID: 30594555
[TBL] [Abstract][Full Text] [Related]
3. AID/APOBEC-network reconstruction identifies pathways associated with survival in ovarian cancer.
Svoboda M; Meshcheryakova A; Heinze G; Jaritz M; Pils D; Castillo-Tong DC; Hager G; Thalhammer T; Jensen-Jarolim E; Birner P; Braicu I; Sehouli J; Lambrechts S; Vergote I; Mahner S; Zimmermann P; Zeillinger R; Mechtcheriakova D
BMC Genomics; 2016 Aug; 17(1):643. PubMed ID: 27527602
[TBL] [Abstract][Full Text] [Related]
4. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
5. Bioinformatic profiling identifies a platinum-resistant-related risk signature for ovarian cancer.
Wu C; He L; Wei Q; Li Q; Jiang L; Zhao L; Wang C; Li J; Wei M
Cancer Med; 2020 Feb; 9(3):1242-1253. PubMed ID: 31856408
[TBL] [Abstract][Full Text] [Related]
6. Clinical and RNA expression integrated signature for urothelial bladder cancer prognosis.
Xiong J; Xiong K; Bing Z
Cancer Biomark; 2018 Feb; 21(3):535-546. PubMed ID: 29226853
[TBL] [Abstract][Full Text] [Related]
7. Development and Validation of an Immune-Related Prognostic Signature for Ovarian Cancer Based on Weighted Gene Coexpression Network Analysis.
An Y; Yang Q
Biomed Res Int; 2020; 2020():7594098. PubMed ID: 33381581
[TBL] [Abstract][Full Text] [Related]
8. Identification and Clinical Validation of a Novel 4 Gene-Signature with Prognostic Utility in Colorectal Cancer.
Ahluwalia P; Mondal AK; Bloomer C; Fulzele S; Jones K; Ananth S; Gahlay GK; Heneidi S; Rojiani AM; Kota V; Kolhe R
Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31387239
[TBL] [Abstract][Full Text] [Related]
9. Identifying prognostic signature in ovarian cancer using DirGenerank.
Wang JY; Chen LL; Zhou XH
Oncotarget; 2017 Jul; 8(28):46398-46413. PubMed ID: 28615526
[TBL] [Abstract][Full Text] [Related]
10. Targeting of topoisomerases for prognosis and drug resistance in ovarian cancer.
Bai Y; Li LD; Li J; Lu X
J Ovarian Res; 2016 Jun; 9(1):35. PubMed ID: 27315793
[TBL] [Abstract][Full Text] [Related]
11. A potential prognostic long non-coding RNA signature to predict metastasis-free survival of breast cancer patients.
Sun J; Chen X; Wang Z; Guo M; Shi H; Wang X; Cheng L; Zhou M
Sci Rep; 2015 Nov; 5():16553. PubMed ID: 26549855
[TBL] [Abstract][Full Text] [Related]
12. Identification of an energy metabolism‑related gene signature in ovarian cancer prognosis.
Wang L; Li X
Oncol Rep; 2020 Jun; 43(6):1755-1770. PubMed ID: 32186777
[TBL] [Abstract][Full Text] [Related]
13. Increased expression of TET3 predicts unfavorable prognosis in patients with ovarian cancer-a bioinformatics integrative analysis.
Cao T; Pan W; Sun X; Shen H
J Ovarian Res; 2019 Oct; 12(1):101. PubMed ID: 31656201
[TBL] [Abstract][Full Text] [Related]
14. Novel gene signatures for prognosis prediction in ovarian cancer.
Bao M; Zhang L; Hu Y
J Cell Mol Med; 2020 Sep; 24(17):9972-9984. PubMed ID: 32666642
[TBL] [Abstract][Full Text] [Related]
15. Comparative transcriptome analysis of matched primary and distant metastatic ovarian carcinoma.
Sallinen H; Janhonen S; Pölönen P; Niskanen H; Liu OH; Kivelä A; Hartikainen JM; Anttila M; Heinäniemi M; Ylä-Herttuala S; Kaikkonen MU
BMC Cancer; 2019 Nov; 19(1):1121. PubMed ID: 31744494
[TBL] [Abstract][Full Text] [Related]
16. Chemo-resistant Gastric Cancer Associated Gene Expression Signature: Bioinformatics Analysis Based on Gene Expression Omnibus.
Liu JB; Jian T; Yue C; Chen D; Chen W; Bao TT; Liu HX; Cao Y; Li WB; Yang Z; Hoffman RM; Yu C
Anticancer Res; 2019 Apr; 39(4):1689-1698. PubMed ID: 30952707
[TBL] [Abstract][Full Text] [Related]
17. A network-pathway based module identification for predicting the prognosis of ovarian cancer patients.
Wang X; Wang SS; Zhou L; Yu L; Zhang LM
J Ovarian Res; 2016 Nov; 9(1):73. PubMed ID: 27806724
[TBL] [Abstract][Full Text] [Related]
18. An 8-gene signature for prediction of prognosis and chemoresponse in non-small cell lung cancer.
Shahid M; Choi TG; Nguyen MN; Matondo A; Jo YH; Yoo JY; Nguyen NN; Yun HR; Kim J; Akter S; Kang I; Ha J; Maeng CH; Kim SY; Lee JS; Kim J; Kim SS
Oncotarget; 2016 Dec; 7(52):86561-86572. PubMed ID: 27863408
[TBL] [Abstract][Full Text] [Related]
19. Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study.
Bagnoli M; Canevari S; Califano D; Losito S; Maio MD; Raspagliesi F; Carcangiu ML; Toffoli G; Cecchin E; Sorio R; Canzonieri V; Russo D; Scognamiglio G; Chiappetta G; Baldassarre G; Lorusso D; Scambia G; Zannoni GF; Savarese A; Carosi M; Scollo P; Breda E; Murgia V; Perrone F; Pignata S; De Cecco L; Mezzanzanica D;
Lancet Oncol; 2016 Aug; 17(8):1137-1146. PubMed ID: 27402147
[TBL] [Abstract][Full Text] [Related]
20. Development and verification of an immune-related gene pairs prognostic signature in ovarian cancer.
Zhang B; Nie X; Miao X; Wang S; Li J; Wang S
J Cell Mol Med; 2021 Mar; 25(6):2918-2930. PubMed ID: 33543590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
